Search
ixekizumab (Taltz)
Indications:
- chronic plaque psoriasis (FDA-approved March 2016) [2]
- psoriatic arthritis [4]
- active ankylosing spondylitis (FDA-approved Aug 2019) [3,4]
Dosage:
- 75-150 mg SQ
Adverse effects:
- injection site reactions
- Tinea
- upper respiratory tract infections
- neutropenia
- development or worsening of inflammatory bowel disease have been reported [2,4]
Mechanism of action:
- humanized monoclonal antibody [4]
- IL17A antibody (similar to brodalumab)
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
dermatologic agent
References
- Leonardi C et al.
Anti-interleukin-17 monoclonal antibody ixekizumab in
chronic plaque psoriasis.
N Engl J Med 2012 Mar 29; 366:1190.
PMID: 22455413
- Brooks M
Ixekizumab (Taltz ) for Plaque Psoriasis Clears FDA
Medscape Oncology. March 22, 2016
http://www.medscape.com/viewarticle/860774
- FDA News Release. March 22, 2016
FDA approves new psoriasis drug Taltz
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491872.htm
- Brooks M
FDA OKs Ixekizumab (Taltz) for Active Ankylosing Spondylitis.
Medscape. Aug 26, 2019.
https://www.medscape.com/viewarticle/917267
- Medical Knowledge Self Assessment Program (MKSAP) 19
American College of Physicians, Philadelphia 2022